Suppr超能文献

口服大麻后口腔液中的大麻素分布情况。

Cannabinoid disposition in oral fluid after controlled smoked cannabis.

机构信息

Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD 21224, USA.

出版信息

Clin Chem. 2012 Apr;58(4):748-56. doi: 10.1373/clinchem.2011.177881. Epub 2012 Jan 24.

Abstract

BACKGROUND

We measured Δ(9)-tetrahydrocannabinol (THC), 11-nor-9-carboxy-THC (THCCOOH), cannabidiol (CBD), and cannabinol (CBN) disposition in oral fluid (OF) following controlled cannabis smoking to evaluate whether monitoring multiple cannabinoids in OF improved OF test interpretation.

METHODS

Cannabis smokers provided written informed consent for this institutional review board-approved study. OF was collected with the Quantisal™ device following ad libitum smoking of one 6.8% THC cigarette. Cannabinoids were quantified by 2-dimensional GC-MS. We evaluated 8 alternative cutoffs based on different drug testing program needs.

RESULTS

10 participants provided 86 OF samples -0.5 h before and 0.25, 0.5, 1, 2, 3, 4, 6, and 22 h after initiation of smoking. Before smoking, OF samples of 4 and 9 participants were positive for THC and THCCOOH, respectively, but none were positive for CBD and CBN. Maximum THC, CBD, and CBN concentrations occurred within 0.5 h, with medians of 644, 30.4, and 49.0 μg/L, respectively. All samples were THC positive at 6 h (2.1-44.4 μg/L), and 4 of 6 were positive at 22 h. CBD and CBN were positive only up to 6 h in 3 (0.6-2.1 μg/L) and 4 (1.0-4.4 μg/L) participants, respectively. The median maximum THCCOOH OF concentration was 115 ng/L, with all samples positive to 6 h (14.8-263 ng/L) and 5 of 6 positive at 22 h.

CONCLUSIONS

By quantifying multiple cannabinoids and evaluating different analytical cutoffs after controlled cannabis smoking, we determined windows of drug detection, found suggested markers of recent smoking, and minimized the potential for passive contamination.

摘要

背景

我们测量了口服液(OF)中 Δ(9)-四氢大麻酚(THC)、11-去甲-9-羧基-THC(THCCOOH)、大麻二酚(CBD)和大麻酚(CBN)的分布,以评估在控制大麻吸烟后监测 OF 中的多种大麻素是否能改善 OF 测试结果的解释。

方法

参与此项经机构审查委员会批准的研究的大麻吸烟者提供了书面知情同意书。在自由吸烟一支 6.8%THC 香烟后,使用 Quantisal™ 设备收集 OF。通过二维 GC-MS 定量检测大麻素。我们根据不同药物检测项目的需求,评估了 8 种替代的截止值。

结果

10 名参与者共提供了 86 份 OF 样本,分别在吸烟前 0.5 小时和吸烟后 0.25、0.5、1、2、3、4、6 和 22 小时采集。吸烟前,4 名和 9 名参与者的 OF 样本分别检测到 THC 和 THCCOOH,但均未检测到 CBD 和 CBN。THC、CBD 和 CBN 的最大浓度均在 0.5 小时内出现,中位数分别为 644、30.4 和 49.0 μg/L。所有样本在 6 小时时均为 THC 阳性(2.1-44.4 μg/L),其中 6 份中有 4 份在 22 小时时仍为阳性。在 3 名参与者(0.6-2.1 μg/L)和 4 名参与者(1.0-4.4 μg/L)中,CBD 和 CBN 仅在 6 小时内呈阳性,而在 22 小时时,5 份和 6 份样本分别呈阳性。THCCOOH 的最大 OF 浓度中位数为 115 ng/L,所有样本在 6 小时时均为阳性(14.8-263 ng/L),其中 6 份中有 5 份在 22 小时时仍为阳性。

结论

通过对受控大麻吸烟后定量检测多种大麻素和评估不同的分析截止值,我们确定了药物检测窗口,发现了近期吸烟的潜在标志物,并最大限度地减少了被动污染的可能性。

相似文献

1
Cannabinoid disposition in oral fluid after controlled smoked cannabis.
Clin Chem. 2012 Apr;58(4):748-56. doi: 10.1373/clinchem.2011.177881. Epub 2012 Jan 24.
2
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
Clin Chem. 2011 Aug;57(8):1127-36. doi: 10.1373/clinchem.2011.164822. Epub 2011 Jun 15.
3
Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.
Drug Test Anal. 2015 Jun;7(6):494-501. doi: 10.1002/dta.1718. Epub 2014 Sep 14.
4
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.
Anal Bioanal Chem. 2013 Oct;405(26):8451-61. doi: 10.1007/s00216-013-7291-5. Epub 2013 Aug 17.
5
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Drug Alcohol Depend. 2013 Jun 1;130(1-3):68-76. doi: 10.1016/j.drugalcdep.2012.10.011. Epub 2012 Nov 10.
6
Impact of oral fluid collection device on cannabinoid stability following smoked cannabis.
Drug Test Anal. 2015 Feb;7(2):114-20. doi: 10.1002/dta.1688. Epub 2014 Jul 3.
7
On-site test for cannabinoids in oral fluid.
Clin Chem. 2012 Oct;58(10):1418-25. doi: 10.1373/clinchem.2012.189001. Epub 2012 Aug 21.
8
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.
Drug Test Anal. 2014 Oct;6(10):1002-10. doi: 10.1002/dta.1632. Epub 2014 Mar 20.
9
Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis.
Clin Chim Acta. 2012 Apr 11;413(7-8):765-70. doi: 10.1016/j.cca.2012.01.011. Epub 2012 Jan 20.
10
Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.
Clin Chem. 2013 Dec;59(12):1770-9. doi: 10.1373/clinchem.2013.207316. Epub 2013 Aug 12.

引用本文的文献

2
Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8285-8309. doi: 10.1007/s00210-024-03185-6. Epub 2024 Jun 8.
5
Development of Mobile Contingency Management for Cannabis Use Reduction.
Behav Ther. 2024 Jan;55(1):1-13. doi: 10.1016/j.beth.2023.03.004. Epub 2023 Apr 5.
7
Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.
Front Pharmacol. 2022 Jul 12;13:919630. doi: 10.3389/fphar.2022.919630. eCollection 2022.
8
Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.
Curr Addict Rep. 2019 Dec;6(4):429-436. doi: 10.1007/s40429-019-00290-y. Epub 2019 Nov 19.
10
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.
Front Pharmacol. 2018 Nov 26;9:1365. doi: 10.3389/fphar.2018.01365. eCollection 2018.

本文引用的文献

2
Cannabinoids in oral fluid following passive exposure to marijuana smoke.
Forensic Sci Int. 2011 Oct 10;212(1-3):227-30. doi: 10.1016/j.forsciint.2011.06.019. Epub 2011 Jul 18.
3
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
Clin Chem. 2011 Aug;57(8):1127-36. doi: 10.1373/clinchem.2011.164822. Epub 2011 Jun 15.
4
The prevalence of alcohol and drugs in sampled oral fluid is related to sample volume.
J Anal Toxicol. 2010 Sep;34(7):416-9. doi: 10.1093/jat/34.7.416.
5
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.
Clin Chem. 2010 Aug;56(8):1261-9. doi: 10.1373/clinchem.2009.141853. Epub 2010 Jun 8.
7
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.
J Chromatogr A. 2010 Feb 26;1217(9):1513-21. doi: 10.1016/j.chroma.2009.12.053. Epub 2010 Jan 4.
9
Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid.
J Anal Toxicol. 2007 Jun;31(5):288-93. doi: 10.1093/jat/31.5.288.
10
Detection of conjugated 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid.
J Anal Toxicol. 2007 May;31(4):187-94. doi: 10.1093/jat/31.4.187.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验